Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| MOTS-c | Semax | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection. | Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril). |
| Timing | Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance. | Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery. |
| Cycle Duration | 8-16 week cycles. | 10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns. |
| Evidence Level | Emerging (strong preclinical) | moderate_human |
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.
Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
8-16 week cycles.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment that rapidly upregulates brain-derived neurotrophic factor (BDNF) and its signaling receptor TrkB in the hippocampus (1.4-fold BDNF protein increase, 3-fold exon III BDNF mRNA increase). It activates dopaminergic and serotonergic brain systems, enhances neurotrophin gene expression (BDNF, NGF), and modulates intracellular calcium dynamics in brain neurons. Semax lacks ACTH's corticotropic activity, acting purely as a nootropic/neuroprotective agent.
Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril).
Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery.
10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →